Cypralis, a life sciences company focused on the discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases (PPIases) has acquired a portfolio of cyclophilin inhibitor assets from SCYNEXIS Inc., a NASDAQ-listed company headquartered in New Jersey, USA.
The transaction involves the transfer of a large library of cyclophilin inhibitor compounds plus associated patents and know-how to Cypralis in return for milestone payments to Scynexis upon the successful progression of Cypralis clinical candidates into later stage clinical studies, and a royalty payable upon product commercialization. The financial terms of the transaction are not disclosed.
Simon Kerr, CEO of Cypralis, commented: “Acquiring the Scynexis cyclosporin analogue library augments our existing assets in the cyclophilin inhibitor space. Cypralis now owns one of the largest and most structurally diverse libraries of cyclophilin inhibitors in the world, with associated IP and sub-type selective compounds in three distinct chemical families. This transaction will enable Cypralis to accelerate its progression towards the clinic, as the company seeks to develop novel, selective cyclophilin inhibitors that can offer new treatment options for serious diseases.”